Positive results from a phase 3 trial of vutrisiran, a new drug from Alnylam for transthyretin-mediated amyloidosis with cardiomyopathy, have been reported. The HELIOS-B study showed a significant reduction in all-cause mortality and cardiovascular events with vutrisiran compared to placebo. The study included 655 adults with the condition, and vutrisiran demonstrated improvements in disease progression and safety. Detailed results will be presented at the European Society of Cardiology conference, and the company plans to submit vutrisiran for regulatory approval later this year. Vutrisiran has the potential to become a new standard of care for this debilitating and fatal disease.
Source link
Promising Results for Vutrisiran in Cardiac Amyloidosis
